A recent study found that ERp29 could potentiate resistance to doxorubicin by up-regulating Hsp27 in breast cancer cells through sequently down-regulating the α subunit of the eukaryotic initiation factor 2 (elF2α) (30), which can trigger apoptotic signals by activation of downstream molecule CHOP (31,32). Here, DDIT3 is linked to breast carcinoma.